Page last updated: 2024-09-04

lonafarnib and Invasiveness, Neoplasm

lonafarnib has been researched along with Invasiveness, Neoplasm in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Kang, JH; Kim, ES; Kyu Woo, J; Lee, HY; Lee, OH; Oh, SH	1
Banerjee, A; Belasco, JB; Blaney, SM; Boyett, JM; Broniscer, A; Frank, E; Geyer, JR; Goldman, S; Gururangan, S; Kieran, MW; Kirschmeier, P; Kun, LE; Onar, A; Packer, RJ; Phillips, P; Pollack, IF; Statkevich, P; Turner, CD; Yver, A; Zhu, Y	1

Trials

1 trial(s) available for lonafarnib and Invasiveness, Neoplasm

Article	Year
Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Cons Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Jul-20, Volume: 25, Issue:21 Topics: Administration, Oral; Adolescent; Adult; Central Nervous System Neoplasms; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Farnesyltranstransferase; Female; Follow-Up Studies; Humans; Infant; Infant, Newborn; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Piperidines; Pyridines; Risk Assessment; Survival Analysis; Treatment Outcome	2007

Article

Year

Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Cons

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Jul-20, Volume: 25, Issue:21

Topics: Administration, Oral; Adolescent; Adult; Central Nervous System Neoplasms; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Farnesyltranstransferase; Female; Follow-Up Studies; Humans; Infant; Infant, Newborn; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Piperidines; Pyridines; Risk Assessment; Survival Analysis; Treatment Outcome

2007

Other Studies

1 other study(ies) available for lonafarnib and Invasiveness, Neoplasm

Article	Year
A multiplicity of anti-invasive effects of farnesyl transferase inhibitor SCH66336 in human head and neck cancer. International journal of cancer, 2012, Aug-01, Volume: 131, Issue:3 Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Farnesyltranstransferase; Female; Head and Neck Neoplasms; Humans; Insulin-Like Growth Factor Binding Protein 3; Matrix Metalloproteinase 2; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Piperidines; Proto-Oncogene Proteins c-akt; Pyridines; Receptor, IGF Type 1; RNA Interference; RNA, Small Interfering; Squamous Cell Carcinoma of Head and Neck; Urokinase-Type Plasminogen Activator	2012

Article

Year

A multiplicity of anti-invasive effects of farnesyl transferase inhibitor SCH66336 in human head and neck cancer.

International journal of cancer, 2012, Aug-01, Volume: 131, Issue:3

Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Farnesyltranstransferase; Female; Head and Neck Neoplasms; Humans; Insulin-Like Growth Factor Binding Protein 3; Matrix Metalloproteinase 2; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Piperidines; Proto-Oncogene Proteins c-akt; Pyridines; Receptor, IGF Type 1; RNA Interference; RNA, Small Interfering; Squamous Cell Carcinoma of Head and Neck; Urokinase-Type Plasminogen Activator

2012